<DOC>
	<DOCNO>NCT01452295</DOCNO>
	<brief_summary>VTI-207 ( NCT01452295 ) design follow subject , treat control , five year completion study participation protocol VTI-206 ( NCT00973817 ) gather information relate incidence liver transplant , incidence type cancer ( ) , survival .</brief_summary>
	<brief_title>Registry Protocol Tracking Trial Subjects After VTI-206 Study Completion</brief_title>
	<detailed_description>Vital Therapies , Inc. ( VTI ) conduct clinical trial VTI-206 subject acute chronic hepatitis ( AOCH ) acute alcoholic hepatitis ( AAH ) treat ELAD system assess safety efficacy therapy . The ELAD system incorporates clone immortalized human liver cell ( C3A cell ) . A hypothetical risk exists , extend period time , may increase incidence tumor subject treat ELAD . The company also collect data related whether patient receive liver transplant survival .</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Failure , Acute</mesh_term>
	<criteria>Subjects participate VTI206 clinical trial . Subjects participate VTI206 clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>liver</keyword>
	<keyword>liver failure</keyword>
	<keyword>acute liver failure</keyword>
	<keyword>ELAD</keyword>
	<keyword>alcoholic hepatitis</keyword>
	<keyword>acute chronic hepatitis</keyword>
</DOC>